Literature DB >> 18372913

Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion.

P Arora1, B D Cuevas, A Russo, G L Johnson, J Trejo.   

Abstract

Hyperactivation of ErbB signaling is implicated in metastatic breast cancer. However, the mechanisms that cause dysregulated ErbB signaling and promote breast carcinoma cell invasion remain poorly understood. One pathway leading to ErbB activation that remains unexplored in breast carcinoma cell invasion involves transactivation by G-protein-coupled receptors (GPCRs). Protease-activated receptor-1 (PAR1), a GPCR activated by extracellular proteases, is overexpressed in invasive breast cancer. PAR1 is also proposed to function in breast cancer invasion and metastasis, but how PAR1 contributes to these processes is not known. In this study, we report that proteolytic activation of PAR1 by thrombin induces persistent transactivation of EGFR and ErbB2/HER2 in invasive breast carcinoma, but not in normal mammary epithelial cells. PAR1-stimulated EGFR and ErbB2 transactivation leads to prolonged extracellular signal-regulated kinase-1 and -2 signaling and promotes breast carcinoma cell invasion. We also show that PAR1 signaling through Galpha(i/o) and metalloprotease activity is critical for ErbB transactivation and cellular invasion. Finally, we demonstrate that PAR1 expression in invasive breast carcinoma is essential for tumor growth in vivo assessed by mammary fat pad xenografts. These studies reveal a critical role for PAR1, a receptor activated by tumor-generated proteases, in hyperactivation of ErbB signaling that promotes breast carcinoma cell invasion.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18372913      PMCID: PMC2874884          DOI: 10.1038/onc.2008.84

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  32 in total

1.  Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection.

Authors:  Takahisa Noma; Anthony Lemaire; Sathyamangla V Naga Prasad; Liza Barki-Harrington; Douglas G Tilley; Juhsien Chen; Philippe Le Corvoisier; Jonathan D Violin; Huijun Wei; Robert J Lefkowitz; Howard A Rockman
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

2.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

3.  The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors.

Authors:  Thomas P J Garrett; Neil M McKern; Meizhen Lou; Thomas C Elleman; Timothy E Adams; George O Lovrecz; Michael Kofler; Robert N Jorissen; Edouard C Nice; Antony W Burgess; Colin W Ward
Journal:  Mol Cell       Date:  2003-02       Impact factor: 17.970

Review 4.  EGFR and cancer prognosis.

Authors:  R I Nicholson; J M Gee; M E Harper
Journal:  Eur J Cancer       Date:  2001-09       Impact factor: 9.162

5.  beta -Arrestins regulate protease-activated receptor-1 desensitization but not internalization or Down-regulation.

Authors:  May M Paing; Amy B Stutts; Trudy A Kohout; Robert J Lefkowitz; JoAnn Trejo
Journal:  J Biol Chem       Date:  2001-11-02       Impact factor: 5.157

Review 6.  Biology of HER2 and its importance in breast cancer.

Authors:  Y Yarden
Journal:  Oncology       Date:  2001       Impact factor: 2.935

7.  Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy.

Authors:  Masanori Asakura; Masafumi Kitakaze; Seiji Takashima; Yulin Liao; Fuminobu Ishikura; Tsuyoshi Yoshinaka; Hiroshi Ohmoto; Koichi Node; Kohichiro Yoshino; Hiroshi Ishiguro; Hiroshi Asanuma; Shoji Sanada; Yasushi Matsumura; Hiroshi Takeda; Shintaro Beppu; Michihiko Tada; Masatsugu Hori; Shigeki Higashiyama
Journal:  Nat Med       Date:  2002-01       Impact factor: 53.440

8.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

Authors:  M A Cobleigh; C L Vogel; D Tripathy; N J Robert; S Scholl; L Fehrenbacher; J M Wolter; V Paton; S Shak; G Lieberman; D J Slamon
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

9.  TACE is required for the activation of the EGFR by TGF-alpha in tumors.

Authors:  Maria Borrell-Pagès; Federico Rojo; Joan Albanell; Josep Baselga; Joaquín Arribas
Journal:  EMBO J       Date:  2003-03-03       Impact factor: 11.598

10.  TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells.

Authors:  Andreas Gschwind; Stefan Hart; Oliver M Fischer; Axel Ullrich
Journal:  EMBO J       Date:  2003-05-15       Impact factor: 11.598

View more
  66 in total

1.  Kallikrein 6 is a novel molecular trigger of reactive astrogliosis.

Authors:  Isobel A Scarisbrick; Maja Radulovic; Joshua E Burda; Nadya Larson; Sachiko I Blaber; Caterina Giannini; Michael Blaber; Alexander G Vandell
Journal:  Biol Chem       Date:  2012-04       Impact factor: 3.915

Review 2.  G protein-coupled receptors: novel targets for drug discovery in cancer.

Authors:  Rosamaria Lappano; Marcello Maggiolini
Journal:  Nat Rev Drug Discov       Date:  2011-01       Impact factor: 84.694

3.  Promotion of human trophoblasts invasion by gonadotropin-releasing hormone (GnRH) I and GnRH II via distinct signaling pathways.

Authors:  Jing Liu; Colin D Maccalman; Yan-ling Wang; Peter C K Leung
Journal:  Mol Endocrinol       Date:  2009-04-16

4.  Regulation of protease-activated receptor 1 signaling by the adaptor protein complex 2 and R4 subfamily of regulator of G protein signaling proteins.

Authors:  Buxin Chen; David P Siderovski; Richard R Neubig; Mark A Lawson; Joann Trejo
Journal:  J Biol Chem       Date:  2013-12-02       Impact factor: 5.157

Review 5.  Tissue factor and PAR2 signaling in the tumor microenvironment.

Authors:  Florence Schaffner; Wolfram Ruf
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-08-06       Impact factor: 8.311

6.  Lgr5 over-expression is positively related to the tumor progression and HER2 expression in stage pTNM IV colorectal cancer.

Authors:  Feng-Juan Gao; Jie-Yu Chen; Hong-Yan Wu; Jiong Shi; Ming Chen; Xiang-Shan Fan; Qin Huang
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

7.  A functional siRNA screen identifies genes modulating angiotensin II-mediated EGFR transactivation.

Authors:  Amee J George; Brooke W Purdue; Cathryn M Gould; Daniel W Thomas; Yanny Handoko; Hongwei Qian; Gregory A Quaife-Ryan; Kylie A Morgan; Kaylene J Simpson; Walter G Thomas; Ross D Hannan
Journal:  J Cell Sci       Date:  2013-09-17       Impact factor: 5.285

Review 8.  Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family.

Authors:  H Michael Shepard; Cathleen M Brdlik; Hans Schreiber
Journal:  J Clin Invest       Date:  2008-11       Impact factor: 14.808

9.  PAR1 inhibition suppresses the self-renewal and growth of A2B5-defined glioma progenitor cells and their derived gliomas in vivo.

Authors:  R Auvergne; C Wu; A Connell; S Au; A Cornwell; M Osipovitch; A Benraiss; S Dangelmajer; H Guerrero-Cazares; A Quinones-Hinojosa; S A Goldman
Journal:  Oncogene       Date:  2015-11-30       Impact factor: 9.867

10.  PAR1 is selectively over expressed in high grade breast cancer patients: a cohort study.

Authors:  Norma A Hernández; Elma Correa; Esther P Avila; Teresa A Vela; Víctor M Pérez
Journal:  J Transl Med       Date:  2009-06-18       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.